5 , 6 In contrast, some agents, such as SGLT2 inhibitors and GLP-1 receptor agonists, may be advantageous with respect to improved renal outcomes with SGLT2 inhibitors as well as improved cardiovascular (CV) outcomes with both of these classes of medications, which is a particular concern as CV effects are common and a leading cause of death among those with diabetes
Without it, purity claims are marketing copy
Only data that had significance is reported in the results and discussion
What has not been established is that any particular compounded preparation performs the way the approved products did in their trials, because compounded preparations are not studied that way
2025.[DOI] 131
Author CB received lecture fees and served as a consultant for Takeda, MSD, Ferring, Abbvie, Galapagos and Janssen